AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01992991 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation of motor cortex
Study NCT01992991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation of motor cortex
Study NCT00520429 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ACCES - Adjusting to Chronic Conditions with Education and Support
Description: The primary objective of this research is to pilot test a brief mental heath treatment specifically tailored to meet the needs of chronically ill patients with anxiety and/or depression. Using an open-trial format, the proposed study will examine the feasibility of a brief psychosocial intervention. Primary outcomes will assess intervention effects on patient and clinician rated symptoms of anxiety and depression. If proven feasible and effective among this group of participants, the intervention (due to its brief format and focus on medically ill patient needs) will possess unique characteristics that will increase the ability of medical care settings to implement mental health treatments, and will provide valuable pilot data for the development of a larger research project to determine the efficacy of this intervention among a larger group of chronically ill patients relative to usual care.
Study NCT05840796 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy protein drink
Description: The calories oral nutrition supplements were 100 kcal, which included 8.4g of protein and phosphorous was excluded in two oral nutrition supplements formula.~Each participant had two packs of nutrition supplement per day for 4months. The 24-h dietary record, blood pressure, plasma glucose, lipid profile, renal function (estimated glomerular filtration rate, eGFR), inflammatory factor levels were analyzed at the baseline and at the 4th month of the study.~The participants were followed up until the 7th month of the study.
Study NCT05840796 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: casein protein drink
Description: The calories oral nutrition supplements were 100 kcal, which included 8.4g of protein and phosphorous was excluded in two oral nutrition supplements formula.~Each participant had two packs of nutrition supplement per day for 4 months. The 24-h dietary record, blood pressure, plasma glucose, lipid profile, renal function (estimated glomerular filtration rate, eGFR), inflammatory factor levels were analyzed at the baseline and at the 4th month of the study.~The participants were followed up until the 7th month of the study.
Study NCT04371133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Adropin (ng/L)
Description: Thawed samples were measured on a Molecular Devices SpectraMax i3 Multi-Mode, Microplate Reader (batch number: SER 35 370-1448, made in Austria) using enzyme linked immunosorbent assay (ELISA).
Study NCT00039286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Study NCT00039286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radionuclide imaging
Study NCT00039286 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Study NCT03531294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: intravitreal 2mg aflibercept injection
Study NCT01022463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine 5 mg BId for 4 weeks
Study NCT01022463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atenolol
Description: 50 mg od for 4 weeks
Study NCT01022463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: 50 mg od for 4 weeks
Study NCT01269086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Preventive Visit
Description: Systematic assessment of health diseases or risk factors in the spouse and adolescent child.
Study NCT01010555 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: Commercially marketed, silicone hydrogel, spherical contact lens
Study NCT04386837 — intervention group
Intervention type: OTHER
Intervention: Turkish Aphasia Rapid Test
Description: Same
Study NCT00852982 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Exercise
Description: Nordic walking, with walking poles, five hours per week during four months
Study NCT01010555 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: Commercially marketed, silicone hydrogel, spherical contact lens
Study NCT01010555 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: Commercially marketed, silicone hydrogel, spherical contact lens
Study NCT01010555 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enfilcon A
Description: Commercially marketed, silicone hydrogel, spherical contact lens
Study NCT00852982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Nordic walking, with walking poles, five hours per week during four months
Study NCT01342263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCDM
Description: The iCDM intervention will be managed by a nurse with experience in chronic disease management who will review patient data, communicate with the patients, implement the Treatment Algorithms and interact with the patients' PCP. Patients will also be able to interact with a dietitian and exercise specialist to support them in their disease management. These personnel will have formal training in principles of the Transtheoretical Model of Change and Social Cognitive Theory.
Study NCT04374630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Commercially available paclitaxel for IV administration will be obtained by clinical sites in US.
Study NCT04374630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Commercially available paclitaxel for IV administration will be obtained by clinical sites in US.
Study NCT04374630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib
Description: Each afuresertib 50 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 50 mg of afuresertib (free base).~Each afuresertib 75 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 75 mg of afuresertib (free base)
Study NCT03612960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes
Description: Very low nicotine content cigarettes
Study NCT03612960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal nicotine content cigarettes
Description: Normal nicotine content cigarettes
Study NCT02305225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Study NCT02924363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI with or without contrast dye
Description: MRI scans of the heart are performed before and after the MitraClip clinical procedure with an FDA cleared device with or without an FDA approved contrast dye.
Study NCT02924363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Blood samples collected to calculate hematocrit for measurements of the CMR extracellular matrix.
Study NCT03827707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noise
Description: Noise applied via headphones during 60 min after meal ingestion
Study NCT03827707 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Silence
Description: Headphones without sound applied during 60 min after meal ingestion
Study NCT03983109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EpiFaith loss of resistance detect syringe
Description: An EpiFaith syringe will be used to detect the loss of resistance and facilitate the needle localization.
Study NCT04000724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging (Text+Step)
Description: Participants receive three culturally competent, theory-based pre-written messages per day sent on a predetermined schedule. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.
Study NCT04000724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WebApp (App+Step)
Description: Participants receive access to a culturally competent password-protected web-based application with transgender-specific resources, support, and health information. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.
Study NCT04000724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information/No Step
Description: Participants in the Information/No Step intervention will receive access to a static website with information about trans health, HIV/STI information and local resources tailored for transgender persons.
Study NCT00455455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optifree RepleniSH Multipurpose Disinfecting Solution
Description: lens care system
Study NCT00455455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ReNu Multiplus Multipurpose Solution
Description: lens care system
Study NCT02214732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: The modified MBCT program for pregnant women is an 8-session group intervention that aims to help women change their relationship to the thoughts, feelings, and bodily sensations that can lead to psychological distress. Participants are guided to recognize and disengage from unhelpful mind states characterized by self-perpetuating patterns of ruminative thought. The intervention was modified to address pregnant women's physical and emotional needs, as well as their risk of perinatal mood episodes.
Study NCT02440711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy storing foot (ESF)
Description: A commercially-available energy storing prosthetic foot
Study NCT01025895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acl reconstruction - double bundle technique
Study NCT02440711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified running specific foot (mRSF)
Description: A running specific prosthetic foot customized for both running and walking activities
Study NCT01275469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 80mg
Description: Hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast.
Study NCT01275469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hard gelatin capsules, oral administration, 4 capsules per day before breakfast.
Study NCT04560738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-CC-92480
Description: Oral
Study NCT04519749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-310
Description: 4D-310 is a novel adeno-associated virus (AAV) gene therapy comprised of two active components: the capsid (4D-C102) and the transgene cassette, which encodes a codon-optimized full length human GLA transgene driven by the CAG promoter. 4D-310 has been engineered so that it cannot replicate (replication incompetent).
Study NCT05855785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dual task exercise
Description: 8-week, 3 times a week, 60-minute group exercise sessions, which were comprised of moderate-to-high intensity exercise and simultaneous cognitive tasks
Study NCT05855785 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: home exercise
Description: 60-minute light intensity home exercise, 4 times a week for 8 weeks
Study NCT02493283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapsone single dose
Description: Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration), urine (0-24 h, 24-48 h, 48-72 h, 72-96 h, 96 -120 h) and feces (on treatment days 1-5)
Study NCT02493283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapsone multiple dose
Description: Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) s.i.d. for 7 days and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration), urine (last treatment day 0-24 h) and feces (on treatment days 12-15)
Study NCT02493283 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: leucocytes
Description: sampling for leucocytes collection: study days -1, 1, 14 and 15
Study NCT02493283 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Met-Hb
Description: sampling before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration, before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration and sampling for additional safety analyses (Met-Hb): study days 10, 12, 14 and hematology on study day 12
Study NCT01959568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrectomy and tamponade
Description: In the double tamponade arm the result of surgery is vitreous cavity filled in a half with perfluorodecalin and in another half - with silicone oil.~In the silicone oil tamponade arm the result of surgery is vitreous cavity filled with conventional or heavy silicone oil, depending on predominant retinal breaks location.
Study NCT01959568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy and tamponade
Description: In the double tamponade arm the result of surgery is vitreous cavity filled in a half with perfluorodecalin and in another half - with silicone oil.~In the silicone oil tamponade arm the result of surgery is vitreous cavity filled with conventional or heavy silicone oil, depending on predominant retinal breaks location.
Study NCT03072433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling Intervention Package
Description: Daily 45 minutes of group teaching for primary caregivers, followed by 45 minutes of supervised play and stimulation with their children for a total of four days. Teaching modules consist of psychosocial stimulation, nutrition and feeding, and water, sanitation and hygiene practices.
Study NCT03072433 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Nutrition and water sanitation and hygiene counseling at any point prior to discharge from hospital as per the local nutrition rehabilitation unit standard of care. In addition, primary caregivers will be stimulated to play with their children in a play area.
Study NCT02851771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal Swab
Study NCT00105768 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Advisor-Teller Money Management-Substance Abuse Counselling
Study NCT03198065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand-made glove setting
Description: The patients receive Hand-made glove setting for single-incision laparoscopic appendectomy
Study NCT03198065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Commercialized single-incision multiport setting
Description: The patients receive commercialized single-incision multiport setting for single-incision laparoscopic appendectomy
Study NCT03973528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: traditional Chinese medicine: tonifying kidney Wan
Description: traditional Chinese medicine : tonifying kidney Wan
Study NCT03914963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrin sealant hemipelvis
Description: Following the manufacturer´s instructions, 5 ml of sealant was sprayed evenly across the entire surgical bed in only one hemipelvis (the treated hemipelvis) after pelvis bilateral lymphadenectomy.
Study NCT03914963 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control hemipelvis
Description: Contralateral hemipelvis not treated with fibrin sealant
Study NCT04145349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study NCT04145349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Administered orally
Study NCT04145349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered orally
Study NCT04145349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Administered IV
Study NCT04145349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Administered IV
Study NCT01025895 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acle reconstruction - single bundle technique
Study NCT06114459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride
Description: Post surgery disinfection
Study NCT04339140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zafirlukast
Description: Oral tablets, 2x daily for 28 day cycle up to 1 year
Study NCT03960463 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcu O2®
Description: Participants randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.
Study NCT05099029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine
Description: EV71 vaccine (\[1 μg total protein + adjuvant 150 μg AI(OH)3\] per dose) Two vaccinations at 28 days apart
Study NCT02311361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 10 mg/kg, mg intravenous (IV), every two weeks, or 1500 mg, IV, every four weeks.
Study NCT05099029 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (\[ adjuvant 150 μg AI(OH)3\] per dose) Two vaccinations at 28 days apart
Study NCT03062839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Description: Melatonin 5 mg taken 30 minutes before bed time
Study NCT03062839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin 5 mg
Description: Melatonin 5 mg taken 30 minutes before bed time
Study NCT03182712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 PUFA Group
Description: Participants received n-3 PUFA capsules (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.
Study NCT03182712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Participants received capsules containing 500 mg of gelatin.Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.
Study NCT01615718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low-intensity transcranial electrical stimulation
Description: Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for 20 minutes - however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.
Study NCT01615718 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low-intensity transcranial electrical stimulation
Description: Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for 20 minutes - however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.
Study NCT01615718 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: low-intensity transcranial electrical stimulation
Description: Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for 20 minutes - however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.
Study NCT04304599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric Elle
Description: The study device is commercially available (CE-marked). It is a device for female intermittent catheterization. Treatment Period will last for 2 weeks. The angulated handle available with the device must be used by each subject at least 10 times.
Study NCT03570164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: End-tidal concentration of sevoflurane is maintained at age-corrected 1.0 minimum alveolar concentration throughout the study period.
Study NCT03570164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: End-tidal concentration of desflurane is maintained at age-corrected 1.0 minimum alveolar concentration throughout the study period.